Cleveland Clinic | Strategic Alliance Partners

Key opinion leaders in multiple myeloma management elucidate the value of clinical trials and share enthusiasm for improving enrollment when possible.

A focused discussion on the regulatory aspects of drug testing and approval, globally, with respect to the setting of multiple myeloma management.

Expert panelists consider best methods in educating patients on their options for therapy following a diagnosis of multiple myeloma.

Comprehensive insight to disparities that may impact a patient’s access to therapy for multiple myeloma and how these may be overcome.

Panelists share a brief discussion on the current treatment armamentarium available to patients with newly diagnosed multiple myeloma.

Experts in multiple myeloma management consider essential tests that aid in the diagnosis and treatment of newly presenting patients.

Brian Gastman MD, discusses how findings from CheckMate76K contributed to the rationale for a biomarker analysis in that trial’s patient population, key findings from this biomarker analysis, and how these findings may inform further research regarding the benefits of immunotherapy in earlier-stage disease.

Aaron T. Gerds, MD, PhD, expands on the potential role of momelotinib in the treatment of patients with myelofibrosis who present with anemia, details the data from MOMENTUM, and explains what FDA approval of momelotinib could mean for the treatment of this patient population.

Logan Roof, MD, discusses the importance of investigating demographic disparities that exist in lung cancer mortality, expands on the results of the population-based CDC database analysis, and discusses potential next steps to address these disparities in the future.

Shilpa Gupta, MD, expands on the updated results from EV-103 in patients with locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin, and details the next steps for investigating the combination of enfortumab vedotin plus pembrolizumab in the ongoing phase 3 EV-302 trial.

Shared insight from key opinion leaders on educational resources made available to physicians and patients, respectively, regarding multiple myeloma management.

Opening its discussion on key unmet needs in multiple myeloma management, a panel of experts discuss key challenges faced when diagnosing patients with multiple myeloma and review the impact of having a multidisciplinary care team.

Logan Roof, MD, discusses findings from a study investigating trends in lung cancer mortality across different sociodemographic populations and locations in the United States between 1999 and 2020.

Megan Kruse, MD, offers advice to community oncologists treating HER2+ metastatic breast cancer and discusses unmet needs in the treatment landscape.

Shilpa Gupta, MD, discusses the enrollment criteria used for the phase 1/2 EV-103 trial in patients with locally advanced or metastatic urothelial carcinoma, and highlights next steps for the investigation of the frontline combination of enfortumab vedotin and pembrolizumab in the phase 3 EV-302 trial.

An overview of agents and treatment strategies currently being investigated in HER2+ metastatic breast cancer.

Megan Kruse, MD, discusses the HER2CLIMB-02 study and the impact it may have on the HER2+ metastatic breast cancer treatment landscape.

Brian Gastman, MD, discusses results from a biomarkers analysis of patients with stage IIB/C melanoma in the phase 3 CheckMate76K trial.

Expert oncologists discuss unmet needs and share final thoughts on the future of treatment of patients with lower-risk MDS.

Clinical insights on approaches to treating HER2+ metastatic breast cancer with central nervous system involvement.

Ralph Boccia, MD, FACP, highlights emerging therapies and the importance of next-generation sequencing for patients with MDS.

Megan Kruse, MD, reviews clinical trial data updates from the 2023 ASCO Annual Meeting on HER2+ metastatic breast cancer.

Expert oncologists discuss management strategies for patients with lower-risk MDS considering upcoming treatment options.

An expert on HER2+ metastatic breast cancer reviews data from the DESTINY-Breast02 and DESTINY-Breast03 trials, which were updated at the 2022 San Antonio Breast Cancer Symposium.

Oncologists review study design and discuss key safety and efficacy data of the COMMANDS trial investigating luspatercept in frontline setting in patients with lower-risk MDS.

Megan Kruse, MD, discusses the evolving treatment landscape for patients with HER2+ metastatic breast cancer.

Shilpa Gupta, MD, discusses the design, methodology, and potential significance of the ongoing phase 3 MAIN-CAV trial in patients with locally advanced/metastatic urothelial carcinoma

Ralph Boccia, MD, FACP, shares his clinical experience using luspatercept to treat patient with lower-risk MDS.

Expert oncologists discuss standard-of-care frontline treatments for patients with lower-risk MDS.

Shilpa Gupta, MD, discusses the 4-year safety and efficacy data derived from the phase 1/2 EV-103 trial in patients with locally advanced or metastatic urothelial carcinoma.